These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17896359)

  • 1. Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX.
    Jasperse B; Valsasina P; Neacsu V; Knol DL; De Stefano N; Enzinger C; Smith SM; Ropele S; Korteweg T; Giorgio A; Anderson V; Polman CH; Filippi M; Miller DH; Rovaris M; Barkhof F; Vrenken H;
    J Magn Reson Imaging; 2007 Oct; 26(4):881-5. PubMed ID: 17896359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agreement between different input image types in brain atrophy measurement in multiple sclerosis using SIENAX and SIENA.
    Neacsu V; Jasperse B; Korteweg T; Knol DL; Valsasina P; Filippi M; Barkhof F; Rovaris M; Vrenken H;
    J Magn Reson Imaging; 2008 Sep; 28(3):559-65. PubMed ID: 18777529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the reproducibility of the SienaX and Siena brain atrophy measures using the ADNI back-to-back MP-RAGE MRI scans.
    Cover KS; van Schijndel RA; van Dijk BW; Redolfi A; Knol DL; Frisoni GB; Barkhof F; Vrenken H; ;
    Psychiatry Res; 2011 Sep; 193(3):182-90. PubMed ID: 21764565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of MRI coregistration on serial short-term brain volume changes in multiple sclerosis.
    Fritz DA; Dwyer MG; Bagnato F; Watts KL; Bratina A; Zorzon M; Durastanti V; Locatelli L; Millefiorini E; Zivadinov R
    Neurol Res; 2006 Apr; 28(3):275-9. PubMed ID: 16687053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1 images in multiple sclerosis.
    Popescu V; Battaglini M; Hoogstrate WS; Verfaillie SC; Sluimer IC; van Schijndel RA; van Dijk BW; Cover KS; Knol DL; Jenkinson M; Barkhof F; de Stefano N; Vrenken H;
    Neuroimage; 2012 Jul; 61(4):1484-94. PubMed ID: 22484407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between inflammatory activity and brain atrophy in natalizumab treated patients.
    Magraner M; Coret F; Casanova B
    Eur J Radiol; 2012 Nov; 81(11):3485-90. PubMed ID: 22391507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SIENA-XL for improving the assessment of gray and white matter volume changes on brain MRI.
    Battaglini M; Jenkinson M; De Stefano N;
    Hum Brain Mapp; 2018 Mar; 39(3):1063-1077. PubMed ID: 29222814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy.
    Steenwijk MD; Amiri H; Schoonheim MM; de Sitter A; Barkhof F; Pouwels PJW; Vrenken H
    Neuroimage Clin; 2017; 15():843-853. PubMed ID: 28794970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentrations of immunoglobulin free light chains in cerebrospinal fluid predict increased level of brain atrophy in multiple sclerosis.
    Nazarov V; Makshakov G; Kalinin I; Lapin S; Surkova E; Mikhailova L; Gilburd B; Skoromets A; Evdoshenko E
    Immunol Res; 2018 Dec; 66(6):761-767. PubMed ID: 30635824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined analysis of global and compartmental brain volume changes in early multiple sclerosis in clinical practice.
    Pichler A; Khalil M; Langkammer C; Pinter D; Bachmaier G; Ropele S; Fuchs S; Enzinger C; Fazekas F
    Mult Scler; 2016 Mar; 22(3):340-6. PubMed ID: 26163072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging.
    Storelli L; Rocca MA; Pagani E; Van Hecke W; Horsfield MA; De Stefano N; Rovira A; Sastre-Garriga J; Palace J; Sima D; Smeets D; Filippi M;
    Radiology; 2018 Aug; 288(2):554-564. PubMed ID: 29714673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods for Brain Atrophy MR Quantification in Multiple Sclerosis: Application to the Multicenter INNI Dataset.
    Storelli L; Pagani E; Pantano P; Piervincenzi C; Tedeschi G; Gallo A; De Stefano N; Battaglini M; Rocca MA; Filippi M;
    J Magn Reson Imaging; 2023 Oct; 58(4):1221-1231. PubMed ID: 36661195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls.
    Alvarez E; Nair KV; Hoyt BD; Seale RA; Sillau S; Miravalle A; Engebretson E; Schurr B; Corboy JR; Vollmer TL; Honce JM
    Mult Scler Relat Disord; 2021 Oct; 55():103170. PubMed ID: 34364034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: comparison of 7 quantification techniques.
    Durand-Dubief F; Belaroussi B; Armspach JP; Dufour M; Roggerone S; Vukusic S; Hannoun S; Sappey-Marinier D; Confavreux C; Cotton F
    AJNR Am J Neuroradiol; 2012 Nov; 33(10):1918-24. PubMed ID: 22790248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced brain extraction improves the accuracy of brain atrophy estimation.
    Battaglini M; Smith SM; Brogi S; De Stefano N
    Neuroimage; 2008 Apr; 40(2):583-589. PubMed ID: 18255315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain volume loss in individuals over time: Source of variance and limits of detectability.
    Narayanan S; Nakamura K; Fonov VS; Maranzano J; Caramanos Z; Giacomini PS; Collins DL; Arnold DL
    Neuroimage; 2020 Jul; 214():116737. PubMed ID: 32171923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis.
    Altmann DR; Jasperse B; Barkhof F; Beckmann K; Filippi M; Kappos LD; Molyneux P; Polman CH; Pozzilli C; Thompson AJ; Wagner K; Yousry TA; Miller DH
    Neurology; 2009 Feb; 72(7):595-601. PubMed ID: 19005170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing longitudinal brain atrophy measurement techniques in a real-world multiple sclerosis clinical practice cohort: towards clinical integration?
    Beadnall HN; Wang C; Van Hecke W; Ribbens A; Billiet T; Barnett MH
    Ther Adv Neurol Disord; 2019; 12():1756286418823462. PubMed ID: 30719080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
    Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
    J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automatic estimation of brain parenchymal fraction in patients with multple sclerosis: a comparison between synthetic MRI and an established automated brain segmentation software based on FSL.
    Yazici I; Krieger B; Bellenberg B; Ladopoulos T; Gold R; Schneider R; Lukas C
    Neuroradiology; 2024 Feb; 66(2):193-205. PubMed ID: 38110539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.